Skip to main content

Table 6 Survival estimates according to prophylactic glutamine use

From: Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer

Survival Glutamine (+) Glutamine (−) P-value
  (N=56) (N=48)  
Overall
Median (months) 21.4 20.4 0.23
2-year (%) 37.0 34.2  
3-year (%) 27.8 22.8  
Locoregional progression free
Median (months) 11.3 14.2 0.11
2-year (%) 18.7 16.4  
3-year (%) 18.7 16.4  
Progression free
Median (months) 10.2 9.0 0.19
2-year (%) 17.5 14.6  
3-year (%) 17.5 14.6